Priority-setting for hospital funding of high-cost innovative drugs and therapeutics: A qualitative institutional case study.

Yasmeen RazviSimonne L HorwitzCeline CressmanDaniel E WangRandi Zlotnik ShaulAvram E Denburg

Published in: PloS one (2024)

This study identifies values and processes to aid in the development and implementation of institutional resource allocation frameworks for high-cost innovative D&Ts.

Keyphrases

healthcare
primary care
genome wide
emergency department
dna methylation
adverse drug